Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
Who is this study for? Adults with Bleeding Esophageal Varices, Hepatocellular Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug, Procedure
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Randomized comparison within the endoscopic esophageal varices ligation versus non-selective beta-blocker in the primary prevention of esophageal variceal bleeding in patients with HCC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 80
Healthy Volunteers: f
View:
• Between 20 and 80 years old
• Hepatocellular carcinoma (HCC) associated with esophageal varices
• F2 or F3 esophageal varices (Beppu et al classification)
• Hepatocellular carcinoma (HCC) associated with portal thrombosis
Locations
Other Locations
Taiwan
Taipei Veterans General Hospital
RECRUITING
Taipei
Contact Information
Primary
Ming-Chih Hou, MD
mchou@vghtpe.gov.tw
886-2-28712121
Time Frame
Start Date: 2009-08
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 200
Treatments
Placebo_comparator: Propranolol
Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
Active_comparator: Esophageal variceal ligation
Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
Related Therapeutic Areas
Sponsors
Leads: Taipei Veterans General Hospital, Taiwan